In a recent study published in the Molecular Therapy journal, researchers assessed the efficacy of the scFv76 antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lung damage.
Study: Spike mutation resilient scFv76 antibody counteracts SARS-CoV-2 lung…
Source: www.news-medical.net – Read more